American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Tallman
    Tallman
  5. Perales
    Perales
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Kernan
    Kernan
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (3844)
  2. Hematologic Malignancies, Division of (3639)
  3. Center for Hematologic Malignancies (3542)
  4. GSK Faculty (1553)
  5. Adult Leukemia (1289)
  6. Sloan Kettering Institute Faculty (1065)
  7. Bone Marrow Transplant (936)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (931)
  9. Lymphoma (898)
  10. Tow Center for Developmental Oncology (TCDO) (863)
Search Within
Formats
  1. Meeting Abstract (3939)
  2. Journal Article (1239)
  3. Research Letter (44)
  4. Review (44)
  5. Editorial (34)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (3844)
  2. Hematologic Malignancies, Division of (3639)
  3. Center for Hematologic Malignancies (3542)
  4. GSK Faculty (1553)
  5. Adult Leukemia (1289)
  6. Sloan Kettering Institute Faculty (1065)

More Groups

People
  1. Sergio Giralt (337)
  2. Andrew Zelenetz (328)
  3. Ross Levine (312)
  4. Martin Tallman (298)
  5. Miguel-Angel Perales (292)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (43)
  2. 2024 (217)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (4951)
  2. Blood Advances (322)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5323)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Targeting T cells with tetravalent bispecific antibodies for the treatment of graft-versus-host disease
    Journal Article

    Espinosa-Cotton, M.; Hoseini, S. S.; Miranda, I. C.; Herrick, J.; Cheung, N. K. V.
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes
    Journal Article

    Valtis, Y. K.; Devlin, S.; Shouval, R.; Rejeski, K.; Corona, M.; De Abia, A. L.; Rivas-Delgado, A.; Luttwak, E.; Cassanello, G.; Landego, I.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: A secondary SWOG analysis
    Journal Article

    Banerjee, R.; Sexton, R.; Cowan, A. J.; Rosenberg, A. S.; Ailawadhi, S.; Rajkumar, S. V.; Kumar, S.; Dispenzieri, A.; Lonial, S.; Durie, B. G. M.; more...
    Blood (2025)

    Fulltext@MSK | Save
  • 24-hour urine testing does not add value to multiple myeloma response assessments: A secondary analysis of BMT CTN 0702
    Meeting Abstract

    Banerjee, R.; Fritz, A. R.; Akhtar, O. S.; Freeman, C. L.; Cowan, A. J.; Shah, N.; Landau, H. J.; Kumar, S.; Vogl, D. T.; Efebera, Y. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Interim results from a phase 2 pivotal study (DALY II USA) of tandem CD20-CD19-directed non-cryopreserved CAR-T cells - Zamtocabtagene autoleucel (Zamto-Cel) in patients with relapsed/refractory diffuse large B cell lymphoma
    Meeting Abstract

    Shah, N. N.; Maziarz, R. T.; Jacobson, C. A.; Johnston, P. B.; Abhyankar, S.; Isufi, I.; Perales, M. A.; Ghosh, M.; Ulrickson, M.; Rosenthal, A. C.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed and/or refractory follicular lymphoma after ≥ 2 prior therapies including those with a history of POD24: 4-year follow-up of a pivotal phase II study
    Meeting Abstract

    Shadman, M.; Bartlett, N. L.; Matasar, M.; Schuster, S. J.; Assouline, S. E.; Sehn, L. H.; Kuruvilla, J.; Giri, P.; Cheah, C. Y.; Dietrich, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Screening for AL amyloidosis in smoldering multiple myeloma
    Meeting Abstract

    Toskic, D.; Mansukhani, M.; Zhou, P.; Scalia, S.; Ma, X.; Fogaren, T.; Lee, L. X.; Chung, A.; Tuchman, S. A.; Bianchi, G.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A randomized phase 2 trial of 28-day (Arm A) versus 14-day (Arm B) schedule of venetoclax + azacitidine in newly diagnosed acute myeloid leukemia patients ≥ 60 years
    Meeting Abstract

    Borate, U.; Huang, Y.; Zeidner, J. F.; Swords, R. T.; Koenig, K. L.; Stein, E. M.; Baer, M. R.; Stock, W.; Madanat, Y. F.; Olin, R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • The prognostic and predictive value of RUNX1 mutations in newly diagnosed acute myeloid leukemia - An international multicenter cohort study
    Meeting Abstract

    Bystrom, R. P.; Bewersdorf, J. P.; Liu, Y.; Schaefer, E. J.; Shallis, R. M.; Boussi, L.; Zucenka, A.; Garciaz, S.; Aguirre, L. E.; DeAngelo, D. J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): TRANSCEND FL 2-year follow-up
    Meeting Abstract

    Nastoupil, L.; Dahiya, S.; Palomba, M. L.; García-Sancho, A. M.; Reguera, J. L.; Kuruvilla, J.; Jaeger, U.; Cartron, G.; Izutsu, K.; Dreyling, M.; more...
    Blood (2024)

    Fulltext@MSK | Save